Brind.
  1. Bolt Biotherapeutics, Inc. stock is traded on the Nasdaq exchange.

Bolt Biotherapeutics CEO William Quinn Sells Shares

3 reports, 1 independent Updated Thu 00:00
No new developments lately Reached 2 outlets in its first 24 hours
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

William Quinn, CEO of Bolt Biotherapeutics, sold 6,545 shares of the company on September 17th. The transaction was valued at $21,729.40, based on an average price of $3.32 per share. The sale was conducted to cover tax withholding obligations related to the vesting of equity awards.

From tickerreport.com

Why it matters

Some supportBrind's analysis of the reports

The sale represented a 15.94% decrease in William Quinn's total stock ownership. While the transaction was tied to tax obligations, insider share sales can influence market perception of the company's financial health.

Bolt Biotherapeutics, Inc. stock is traded on the Nasdaq exchange.

From tickerreport.com

Who's involved

  • William QuinnSold 6,545 shares of Bolt Biotherapeutics, Inc. stock

Keep exploring

Part of

Bolt Biotherapeutics, Inc. stock is traded on the Nasdaq exchange. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
2 more outlets ran the same wire story